癌症免疫治疗:快速演变的临床格局中的机遇与挑战
癌症免疫治疗已成为强有力的治疗方式,免疫检查点阻断的临床成功凸显了跨瘤种治疗免疫系统的普适性和独特特征。免疫相关不良事件、非典型缓解模式、持久缓解和明确的总生存获益区别于细胞毒治疗。当前挑战包括将免疫治疗纳入辅助和新辅助治疗、优化剂量方案和疗程、开发早期准确捕捉总生存获益的新型替代终点,以及优先开发指导患者选择的生物标志物。
要点
- 免疫检查点阻断(CTLA-4、PD-1、PD-L1拮抗剂)的临床成功确立了免疫治疗的地位。
- 免疫相关不良事件、非典型缓解模式、持久缓解和明确总生存获益是免疫治疗区别于细胞毒治疗的特征。
- 当前挑战包括辅助/新辅助治疗整合、剂量方案疗程优化、新型替代终点开发和生物标志物指导患者选择。
核心结论
- 免疫治疗已使部分患者将癌症从死亡判决转变为慢性病。
- 通过明智的循证决策开发下一代免疫治疗,癌症应成为可治疗、可治愈甚至可预防的疾病。
研究设计与样本
- 综述,检索范围未在原文中报告。
主要发现
- 免疫检查点阻断(CTLA-4、PD-1和PD-L1拮抗剂)的近期临床成功凸显了跨瘤种治疗免疫系统的普适性和癌症免疫治疗的独特特征。
- 免疫相关不良事件、非典型临床缓解模式、持久缓解和明确的总生存获益将癌症免疫治疗与细胞毒癌症治疗区分开来。
- 转化非缓解者为缓解者的联合免疫治疗正在快速发展。
关键数值与推荐
- 原文未报告具体标准与数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer immunotherapy is now established as a powerful way to treat cancer. The recent clinical success of immune checkpoint blockade (antagonists of CTLA-4, PD-1 and PD-L1) highlights both the universal power of treating the immune system across tumour types and the unique features of cancer immunotherapy. Immune-related adverse events, atypical clinical response patterns, durable responses, and clear overall survival benefit distinguish cancer immunotherapy from cytotoxic cancer therapy. Combination immunotherapies that transform non-responders to responders are under rapid development. Current challenges facing the field include incorporating immunotherapy into adjuvant and neoadjuvant cancer therapy, refining dose, schedule and duration of treatment and developing novel surrogate endpoints that accurately capture overall survival benefit early in treatment. As the field rapidly evolves, we must prioritise the development of biomarkers to guide the use of immunotherapies in the most appropriate patients. Immunotherapy is already transforming cancer from a death sentence to a chronic disease for some patients. By making smart, evidence-based decisions in developing next generation immunotherapies, cancer should become an imminently treatable, curable and even preventable disease.
引用
- Emens LA, Ascierto PA, Darcy PK, et al. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017. PMID: 28623775. doi:10.1016/j.ejca.2017.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。